Immunology company Nucleome Therapeutics announced on Monday the appointment of Dr Michelle Morrow as its chief scientific officer (CSO), effective 23 February 2026.
Dr Morrow has two decades of experience in drug discovery and development and executing R&D strategy across biotech and large pharma.
Most recently Dr Morrow was CSO at Avacta Therapeutics, providing strategic leadership of discovery and preclinical research and leading its oncology programme through candidate selection to IND approval. Earlier, she was SVP, head of invoX Therapeutics Innovation, following its acquisition of F-star Therapeutics.
Citius Oncology signs LYMPHIR distribution agreement with Uniphar
Ribo and Madrigal sign global siRNA licensing deal
BillionToOne launches two new add-on liquid biopsy applications for Northstar Select
Iterion Therapeutics reports first patient dosed in clinical study of tegavivint
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
Median Technologies secures FDA clearance for AI lung cancer screening software
Insilico Medicine names new vice president, Clinical Development – Oncology
Kelun-Biotech reports fourth indication for sac-TMT approved by NMPA in HR+/HER2- breast cancer
Innovent Biologics collaborates with Eli Lilly to develop new oncology and immunology treatments
K36 Therapeutics completes first patient cohort dosing for Phase 1 trial of KTX-2001
Hologic receives FDA approval for Aptima HPV assay as primary screening option
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082